SARS-CoV-2 viral load is associated with increased disease severity and mortalityJesse Fajnzylber, Michaël Desjardins, Edward T. Ryan et al.|Nature Communications|2020Cited by 981
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1Jeffrey L. Lennox, Raphael J. Landovitz, Heather J. Ribaudo et al.|Annals of Internal Medicine|2014Cited by 260
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In VivoAthe Tsibris, Daniel R. Kuritzkes, Bette Korber et al.|PLoS ONE|2009Cited by 233
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meetingBoris Jülg, Bruce D. Walker, Lynda Dee et al.|The Lancet HIV|2019Cited by 206
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151